Trial Profile
A RCT Study to Evaluate the Safety and Efficacy of the Fixed Day-5 Antagonist Protocol Versus the Flexible Antagonist Protocol for the Controlled Ovarian Stimulation in Chinese Women With Predicted High Ovarian Response
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Choriogonadotropin alfa (Primary) ; Follitropin beta (Primary) ; Ganirelix (Primary) ; Triptorelin (Primary)
- Indications Female infertility
- Focus Therapeutic Use
- 31 Dec 2015 New trial record